70 results about "Platelet activation" patented technology

An implantable pump system is provided, including an implantable blood pump suitable for use as a partial support assist device, the system further including an extracorporeal battery and a controller coupled to the implantable pump, and a programmer selectively periodically coupled to the controller to configure and adjust operating parameters of the implantable pump. The implantable pump includes a flexible membrane coupled to an electromagnetic actuator including a magnetic assembly and electromagnetic assembly, so that when the electromagnetic assembly is energized, the electromagnetic assembly causes wavelike undulations to propagate along the flexible membrane to propel blood through the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The invention belongs to the technical field of biological medicines, and relates to a Rubicon permeable membrane peptide and application thereof. Specifically, the permeable membrane peptide fragment sequence is designed on the basis of an amino acid sequence of interaction of Rubi protein and Btk, and seven permeable membrane sections of arginine are connected to the tail end of the permeable membrane peptide fragment sequence through disulfide bonds. Immunofluorescence experiments prove that the peptide fragment can efficiently penetrate a platelet membrane to enter cells, and co-immunoprecipitation experiments prove that the peptide fragment has strong affinity with Btk. Platelet aggregation experiments show that the peptide fragment can significantly inhibit platelet activation under collagen stimulation. In an animal model, the peptide fragment is injected before instantaneous middle cerebral artery occlusion or reperfusion of a mouse, and ischemia-reperfusion injury can be effectively relieved. The invention provides a novel potential drug candidate for treating thrombotic diseases and ischemia-reperfusion injury.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The present invention discloses the use of HMG-CoA and its pharmaceutically acceptable salts for preparing a platelet preservative. The present invention has confirmed that adding HMG-CoA or its pharmaceutically acceptable salts to platelets to be preserved can effectively alleviate platelet activation and apoptosis, while prolonging the in vivo survival period of platelets after platelet transfusion and protecting the hemostatic function of platelets.

The application discloses a multifunctional blood vessel stent with a negative Poisson's ratio structure and a preparation method thereof, relates to the technical field of medical devices, and comprises the construction of a blood vessel stent model with a negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface biomimetic modification treatment. The stent can better adapt to the deformation of a blood vessel by virtue of the negative Poisson's ratio characteristic, reduces incompatibility caused by different deformation steps, the structure of the stent is round and smooth, blood flow turbulence and vortex at sharp corners of a traditional stent can be effectively avoided, the hemodynamic performance is improved, the risk of platelet activation and thrombosis is reduced, a surface gradient coating is prepared, multi-mechanism synergy is realized, and the formation of an endothelial layer on the surface of the stent is facilitated.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

An implantable pump system is provided, suitable for use as a left ventricular assist device (LVAD) system, having an implantable pump, a battery, a controller, and a programmer. The implantable pump includes a flexible membrane coupled to an actuator assembly via a skirt that extends toward the inlet of the pump and curves to guide blood toward the outlet. The actuator assembly is magnetically engageable with electromagnetic coils, so that when the electromagnetic coils are energized, the actuator assembly causes wavelike undulations to propagate along the flexible membrane to propel blood from the inlet, across the skirt, and through the outlet of the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

In an illustrative embodiment, methods and system for increasing coagulation potential and / or triggering a higher platelet activation rate in a subject via auricular neurostimulation include contacting skin of the subject with one or more therapeutic electrodes, each electrode positioned in a respective region of nerve structures of the auriculotemporal nerve (ATN), nerve structures connected to the ATN, nerve structures of the auricular branch of the vagus nerve (ABVN), or nerve structures connected to the ABVN, applying, to the electrodes, one or more stimulation patterns.

The present invention discloses engineered platelets carrying platelet activation inhibitor nanoparticles, a preparation method and application thereof, which belongs to the field of pharmaceutical technology and relates to a preparation method of engineered platelets carrying ticagrelor nanoparticles and its therapeutic use in malignant solid tumors. The preparation of the engineered platelets described in the present invention includes the steps of extracting and purifying platelets, preparing gelatin nanoparticles loaded with platelet activation inhibitors, anchoring the nanoparticles to the outer surface of platelets, etc. The engineered platelets of the present invention are targeted to reach the tumor site by recruiting tumor-associated platelets in the body, and specifically respond to matrix metalloproteinases to release the carried platelet activation inhibitor, thereby inhibiting the activation of platelets in the tumor microenvironment, enhancing tumor vascular leakage, alleviating the immunosuppressive microenvironment, and effectively enhancing the effects of chemotherapy and immunotherapy.

The invention discloses a preparation method of a silk conical artificial blood vessel with anticoagulation / endothelialization promotion functions, which comprises the following steps: preparing an artificial blood vessel for intracavity isolation through silk and polyester yarns, and successfully constructing a phosphorylcholine / heparin bionic functional coating on the surface of the blood vessel by using dopamine hydrochloride and hexamethylenediamine. According to the method, phosphorylcholine / heparin is combined with surface coating modification, and a novel intracavitary isolated blood vessel with excellent biological functions and mechanical properties is constructed. The structure of the artificial blood vessel is more matched with the shape of the inner wall of the blood vessel, blood flow distribution and tissue regeneration are facilitated, the anticoagulant property and endothelialization ability of the artificial blood vessel are effectively improved through the phosphorylcholine / heparin coating, protein adsorption and platelet activation can be remarkably reduced, the blood coagulation cascade reaction can be blocked, endothelial cell adhesion and proliferation can be accelerated, and the risk of acute thrombus after operation can be reduced. The method provides a new technical path for design and functionalization of the conical artificial blood vessel in the intracavitary isolation operation, and has important clinical application prospects.

The present invention relates to the technical field of the biopharmaceutical industry, and specifically to a Platycladus orientalis leaf extract and a preparation method thereof, comprising the following raw materials: a modified Platycladus orientalis leaf extract, a modified total saponin of Panax notoginseng, Panax notoginseng, fibrin, chitosan, iron oxide, glycerol, and a modified spinach solution. In the present invention, the modified Platycladus orientalis leaf extract, the modified total saponin of Panax notoginseng, and the modified spinach solution work together through a synergistic effect. The modified Platycladus orientalis leaf extract contains a relatively high amount of volatile oil, which can stimulate platelet aggregation and promote the release of coagulation factors. The modified total saponin of Panax notoginseng can inhibit excessive platelet activation and aggregation, preventing thrombosis. The modified Platycladus orientalis leaf extract and the modified total saponin of Panax notoginseng can jointly promote platelet aggregation and the release of coagulation factors to accelerate blood coagulation. The modified spinach solution promotes the synthesis and release of coagulation factors by providing vitamin K, thereby accelerating blood coagulation. The three form a dynamic equilibrium system, which promotes blood coagulation through a synergistic effect, achieving a hemostatic effect.

The present application relates to a kind of preservative solution for prolonging the in vitro storage period of platelet and its preparation method, containing baicalin 4.50~6.00g, baicalein 3.00~3.40g, sodium citrate 1.50~2.00g, citric acid 0.20~0.50g, glucose 7.90~8.50g per liter of preservative solution, and the remaining component is distilled water.The preservative solution of the present application adds a certain proportion of baicalin and baicalein, and the composition has a synergistic effect on inhibiting platelet activation, protection and inhibition of platelet aggregation, can prolong the in vitro platelet normal temperature storage time, and the normal temperature storage time can reach 16d.

The present invention relates to the technical field of medicine, and to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of Ginkgolide B by means of a hydroxyl group at the 10-position and ester derivatives of carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts. Ginkgolide B is used as a parent body and is prepared by means of chemical structure modification so as to achieve the goals of improving solubility, increasing bioavailability and enhancing healing efficacy. The prepared compound and carboxylate salts thereof have significant platelet activating factor antagonism, an anticoagulant effect and an anti-acute cerebral ischemia effect, and can be used for preparing a drug for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, as well as inflammation, asthma and other diseases related to a platelet activating factor.

The invention relates to an application of a patent medicine Tenapanor approved by FDA in preparing a medicament for resisting platelet and arterial thrombosis. The medicament can be used for effectively inhibiting platelet activation and aggregation and arterial thrombosis block formation. The invention relates to an FDA approved patent medicine Tanipanol capable of effectively inhibiting platelet activation and aggregation induced by a natural agonist ADP and carotid artery and mesenteric artery thrombosis. Tanipamox is used as a novel candidate drug for resisting formation of platelets and arterial thrombosis blocks in fundamental research of thrombotic diseases, and has potential application value in prevention and treatment of arterial thrombosis related diseases.

This disclosure provides an antibody constructs that specifically bind CD9 with high affinity. These antibody constructs include a set of novel heavy chain and light chain complementarity determining regions (CDRs) sequences, optionally humanized variable regions, and engineered Fc region of the heavy chain constant region in order to eliminate undesirable platelet activation. The present invention also provides methods for diagnosing and treating conditions including cancer characterized by the aberrant expression of CD9 in the pertinent tissue and cells through the use of these anti-CD9 antibody constructs.

The invention discloses a lophatherum gracile extract in preparation of a medicine for treating and preventing thrombosis and application of the lophatherum gracile extract in preparation of the medicine for treating and preventing thrombosis, and the medicine comprises the lophatherum gracile extract. The common lophatherum herb extract can inhibit platelet agonist-induced platelet blood clot formation so as to prevent and treat thrombosis, and can inhibit a platelet agonist-induced platelet aggregation function so as to prevent and treat thrombosis. A platelet activation function induced by a platelet agonist can be inhibited so as to prevent and treat thrombosis, and platelet microtubule morphological change induced by the platelet agonist can be inhibited so as to prevent and treat thrombosis; the invention proves that the lophatherum gracile extract has the effects of inhibiting platelet aggregation, activation, particle release and microtubule morphological change for the first time, has small toxic and side effects, provides a new research and development direction for clinical treatment of thrombotic diseases, and shows that the lophatherum gracile extract can be used as a new type of health care product medicine for preventing thrombotic diseases.

The invention relates to the technical field of medical examination and analysis, in particular to a platelet activation marker detection method which at least comprises the following steps: mixing a sample solution, a TXB2 isotope internal standard solution and a precipitator, and carrying out vortex treatment and centrifugal treatment to obtain a serum sample; a serum sample is subjected to LC-MS / MS testing, the content of thromboxane B2 in the sample is determined on the basis of a standard curve, quantitative detection of the content of TXB2 in serum is achieved by optimizing pretreatment and LC-MS / MS (liquid chromatography-tandem mass spectrometry) parameter conditions, and compared with a traditional ELISA method, the sensitivity is higher, the accuracy is higher, the result reproducibility is good, the method is more stable and reliable, and the method is suitable for large-scale popularization and application. Popularization and implementation are easy.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

To provide purified platelet-derived exosome dry powder and a method for manufacturing the purified platelet-derived exosome dry powder that make it possible to effectively relieve or treat inflammation or injury.SOLUTION: Manufacturing steps in the method comprise: (a) taking one unit of a solution derived from blood and containing platelets, and performing a process of purifying platelets to obtain a pure platelet solution; (b) performing an activation process to activate platelets in the pure platelet solution and release exosomes to obtain an activated pure platelet solution, where the activation process is a co-treatment process with collagen and thrombin; (c) performing a purification process to obtain a purified platelet-derived exosome solution; and (d) performing a drying process on the purified platelet-derived exosome solution to obtain purified platelet-derived exosome dry powder containing a plurality of platelet-derived exosomes.SELECTED DRAWING: Figure 2

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.

The invention belongs to the technical field of medicine, particularly relates to application of mGluR5 agonist CHPG in preparation of antithrombotic drugs, and proves that the mGluR5 agonist CHPG has an antithrombotic effect for the first time through platelet function detection, activation index analysis, a FeCl3 induced mouse artery injury model and protein phosphorylation detection. Researches show that the mGluR5 agonist CHPG significantly reduces the risk of thrombosis by inhibiting platelet activation, and has an antithrombotic application potential.